Analyzing OvaScience (OVAS) & The Competition

OvaScience (NASDAQ: OVAS) is one of 187 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its competitors? We will compare OvaScience to related companies based on the strength of its dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Profitability

This table compares OvaScience and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
OvaScience -20,090.13% -68.71% -60.49%
OvaScience Competitors -4,460.18% -494.49% -42.74%

Volatility & Risk

OvaScience has a beta of 3.73, indicating that its stock price is 273% more volatile than the S&P 500. Comparatively, OvaScience’s competitors have a beta of 1.47, indicating that their average stock price is 47% more volatile than the S&P 500.

Earnings and Valuation

This table compares OvaScience and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
OvaScience $650,000.00 -$82.25 million -0.64
OvaScience Competitors $217.40 million -$39.40 million -63.49

OvaScience’s competitors have higher revenue and earnings than OvaScience. OvaScience is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings and target prices for OvaScience and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OvaScience 1 1 1 0 2.00
OvaScience Competitors 668 2535 6709 134 2.63

OvaScience currently has a consensus target price of $8.00, indicating a potential upside of 577.97%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 12.59%. Given OvaScience’s higher possible upside, research analysts plainly believe OvaScience is more favorable than its competitors.

Institutional & Insider Ownership

55.1% of OvaScience shares are held by institutional investors. Comparatively, 49.2% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 9.5% of OvaScience shares are held by insiders. Comparatively, 14.8% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

OvaScience competitors beat OvaScience on 8 of the 13 factors compared.

OvaScience Company Profile

OvaScience, Inc. is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue. The Company’s AUGMENT treatment is designed to improve egg health by supplementing a mitochondrial deficiency. With the AUGMENT treatment, energy-producing mitochondria from a patient’s own EggPC cells are added to the patient’s mature eggs during the in vitro fertilization process to supplement the existing mitochondria. Its OvaPrime treatment is a fertility treatment designed to replenish a woman’s ovary by increasing her egg reserve using her own EggPC cells. Its OvaTure treatment is a fertility treatment that seeks to create mature fertilizable eggs in vitro from a woman’s own EggPC cells without the need for hormone hyperstimulation.

Receive News & Ratings for OvaScience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets


Leave a Reply

 
© 2006-2018 BBNS.